At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers are assessing a combination of medications to see if they work well against upper digestive cancers. The people in this study have esophagus, stomach, or gastro-esophageal junction cancers that spread and keep growing after treatment.
-
Researchers want to find the best dose of BH-30236 to treat people with leukemia. This study includes people with acute myelogenous leukemia (AML) that relapsed (came back) after treatment. It also includes people with higher-risk myelodysplastic syndrome (MDS). Higher-risk means a disease has a higher chance of coming back or not responding to standard treatment.
-
Researchers are comparing different sequences of therapy for people with newly diagnosed multiple myeloma. All participants will get cilta-cel CAR T-cell therapy, a form of immunotherapy made from your own white blood cells.
-
In this study, researchers want to find the best dose of XmAb819 to treat kidney cancer. The people in this study have clear cell renal cell cancer that keeps growing or came back after standard treatments.
-
Researchers are doing this study to find out whether giving the investigational drug REGN5668 with cemiplimab immunotherapy or with REGN4018 is a safe treatment for people with ovarian, peritoneal, or fallopian tube cancer. They will also try to find the highest dose of REGN5668 that can be given safely with cemiplimab or with REGN4018.
-
Doctors are assessing a new photodynamic therapy (PDT) for prostate cancer that has not spread beyond the prostate. This treatment is performed in an operating room while you are under general anesthesia.
-
Researchers are comparing two new combination drug treatments with the standard therapy for multiple myeloma. The people in this study have multiple myeloma that is newly diagnosed. In addition, they cannot have an autologous stem cell transplant with high-dose chemotherapy.
- A Phase I Study of Codrituzumab in Children and Young Adults with Recurrent or Persistent Solid Tumors
Full Title A Multi-Center Phase I Study of Codrituzumab in Pediatric Patients with Relapsed or Refractory Glypican 3 (GPC3) Expressing Extra-Cranial Solid Tumors
Purpose
The purpose of this study is to find the highest dose of the investigational drug codrituzumab that can be given safely in children and young adults with solid tumors that came back or continued to grow despite treatment. Codrituzumab works by targeting a protein called GPC3, which can drive the growth of some forms of cancer that affect children and young adults. It is given intravenously (by vein).
Who Can Join
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have a solid tumor that came back or continued to grow despite prior treatment.
- Patients’ tumors must make the GPC3 protein, which is most often seen in these childhood cancers: hepatoblastoma, hepatocellular carcinoma, undifferentiated embryonal sarcoma of the liver, rhabdomyosarcoma, rhabdoid tumor, and Wilms tumor.
- Patients should recover from the serious side effects of previous therapies before receiving codrituzumab.
- This study is for patients age 1-21 years.
For more information about this study and to inquire about eligibility, please contact 1-833-MSK-KIDS.
Protocol
20-489Phase
Phase I (phase 1)Disease Status
Relapsed or RefractoryInvestigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT04928677ClinicalTrials.gov
- A Phase 3 Study Assessing Dara-VCD Chemotherapy Alone or With a Stem Cell Transplant for People With Newly Diagnosed AL Amyloidosis
Full Title A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis (S2213) (CIRB)
Purpose
Researchers are comparing combination chemotherapy alone or with a stem cell transplant for people with amyloid light chain (AL) amyloidosis. The people in this study have newly diagnosed AL amyloidosis. The chemotherapy includes daratumumab, cyclophosphamide, bortezomib and dexamethasone (Dara-VCD).
If you join this study, you will be randomly assigned to get one of these treatments:
- Dara-VCD alone.
- Dara-VCD followed by a stem cell transplant with melphalan. Giving melphalan before a stem cell transplant helps kill cancer cells and makes room for new blood-forming cells to grow.
A stem cell transplant with melphalan after Dara-VCD may kill more cancer cells in people with newly diagnosed AL amyloidosis.
Who Can Join
To join this study, there are a few conditions. You must:
- Have newly diagnosed AL amyloidosis.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Heather Landau’s office at 646-608-3740.
Protocol
25-107Phase
Phase III (phase 3)Investigator
Co-Investigators
Locations
ClinicalTrials.gov ID
NCT06022939ClinicalTrials.gov
-
Researchers want to find the best dose of FOG-001 to use in people with advanced cancer. This study focuses on people who have colorectal and other digestive cancers that spread and keep growing after treatment.